Literature DB >> 11250929

Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I.

M Brink1, S R Price, J Chrast, J L Bailey, A Anwar, W E Mitch, P Delafontaine.   

Abstract

We previously showed that angiotensin II (ang II) infusion in the rat produces cachexia and decreases circulating insulin-like growth factor I (IGF-I). The weight loss derives from an anorexigenic response and a catabolic effect of ang II. In these experiments we assessed potential catabolic mechanisms and the involvement of the IGF-I system in these responses to ang II. Ang II infusion caused a significant decrease in body weight compared with that of pair-fed control rats. Kidney and left ventricular weights were significantly increased by ang II, whereas fat tissue was unchanged. Skeletal muscle mass was significantly decreased in the ang II-infused rats, and a reduction in lean muscle mass was a major reason for their overall loss of body weight. In skeletal muscles, ang II did not significantly decrease protein synthesis, but overall protein breakdown was accelerated; inhibiting lysosomal and calcium-activated proteases did not reduce the ang II-induced increase in muscle proteolysis. Circulating IGF-I levels were 33% lower in ang II rats vs. control rats, and this difference was reflected in lower IGF-I messenger RNA levels in the liver. Moreover, IGF-I, IGF-binding protein-3, and IGF-binding protein-5 messenger RNAs in the gastrocnemius were significantly reduced. To investigate whether the reduced circulating IGF-I accounts for the loss in muscle mass, we increased circulating IGF-I by coinfusing ang II and IGF-I, but this did not prevent muscle loss. Our data suggest that ang II causes a loss in skeletal muscle mass by enhancing protein degradation probably via its inhibitory effect on the autocrine IGF-I system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11250929     DOI: 10.1210/endo.142.4.8082

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  57 in total

Review 1.  Ace inhibitors as a therapy for sarcopenia - evidence and possible mechanisms.

Authors:  D Sumukadas; M D Witham; A D Struthers; M E T McMurdo
Journal:  J Nutr Health Aging       Date:  2008 Aug-Sep       Impact factor: 4.075

2.  Use of ACE inhibitors is associated with elevated levels of IGFBP-3 among hypertensive older adults: results from the IlSIRENTE study.

Authors:  Graziano Onder; Rosa Liperoti; Andrea Russo; Ettore Capoluongo; Angelo Minucci; Paola Lulli; Matteo Cesari; Marcello Maggio; Roberto Bernabei; Francesco Landi
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

Review 3.  Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia.

Authors:  G Onder; C Della Vedova; F Landi
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

Review 4.  Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review.

Authors:  Benjamin H L Tan; James A Ross; Stein Kaasa; Frank Skorpen; Kenneth C H Fearon
Journal:  J Genet       Date:  2011-04       Impact factor: 1.166

5.  Angiotensin II-induced reduction in body mass is Ang II receptor mediated in association with elevated corticosterone.

Authors:  Rudy M Ortiz; Hiroyuki Kobori; Debra Conte; L Gabriel Navar
Journal:  Growth Horm IGF Res       Date:  2010-05-18       Impact factor: 2.372

6.  Angiotensin II induced catabolic effect and muscle atrophy are redox dependent.

Authors:  Laura C Semprun-Prieto; Sergiy Sukhanov; Tadashi Yoshida; Bashir M Rezk; Romer A Gonzalez-Villalobos; Charlotte Vaughn; A Michael Tabony; Patrice Delafontaine
Journal:  Biochem Biophys Res Commun       Date:  2011-05-06       Impact factor: 3.575

7.  1-Sarcosine-angiotensin II infusion effects on food intake, weight loss, energy expenditure, and skeletal muscle UCP3 gene expression in a rat model.

Authors:  S A Cichello; R S Weisinger; J Schuijers; M Jois
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-03-11       Impact factor: 12.910

8.  Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting.

Authors:  Yao-Hua Song; Yangxin Li; Jie Du; William E Mitch; Nadia Rosenthal; Patrick Delafontaine
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

9.  Angiotensin-Converting Enzyme Inhibitors and Parameters of Sarcopenia: Relation to Muscle Mass, Strength and Function: Data from the Berlin Aging Study-II (BASE-II).

Authors:  Dominik Spira; Jeremy Walston; Nikolaus Buchmann; Jivko Nikolov; Ilja Demuth; Elisabeth Steinhagen-Thiessen; Rahel Eckardt; Kristina Norman
Journal:  Drugs Aging       Date:  2016-11       Impact factor: 3.923

Review 10.  Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults.

Authors:  Silvia Giovannini; Emanuele Marzetti; Stephen E Borst; Christiaan Leeuwenburgh
Journal:  Mech Ageing Dev       Date:  2008-08-13       Impact factor: 5.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.